Ranked "Exceptional" by F1000, this study shows that patient preference between two equally effective treatments for depression, can have a dramatic impact on therapeutic outcome. Faculty of 1000 Medicine
In the sixth commentary of a 7 part-series, Murray Epstein talks with Jiguang Wang from the Shanghai Institute of Hypertension about the value of new mineralocorticoid receptor antagonists in China. Medscape Nephrology